JPRN-UMIN000003751尚未招募2 期
A phase II feasibility trial of Gemcitabine Hydrochloride and Krestin combination therapy in pancreatic cancer after surgery. - A phase II feasibility trial of Gemcitabine Hydrochloride and Krestin combination therapy in pancreatic cancer after surgery.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Active double cancer. 2)Patients with severe myelosuppression. 3)Patients who receiving radiation therapy to the chest. 4)Patients with severe infection. 5)Patients with pulmonary fibrosis or interstitial lung disease. 6)Pregnant patients. 7)Patients with insanity or psychological symptom.
研究者
相似试验
已完成
2 期
A randomized controlled trial of gemcitabine hydrochloride plus S-1 combination (GS) therapy and gemcitabine hydrochloride (Gem) therapy alone for patients with pancreatic cancer who are 75 years or older.Pancreatic cancerJPRN-UMIN000025747ational Hospital Organization Shikoku Cancer Center100
未知
2 期
A Phase II multicenter trial of Gemcitabine in combination with R1415 (erlotinibhydrochloride) in patients with unresectable pancreatic cancer (locally advanced or metastatic)Pancreatic cancerJPRN-jRCT2080220332Chugai Pharmaceutical Co., Ltd.
进行中（未招募）
不适用
Phase II trial of the addition of gemcitabine to 131I-MIBG therapy in paediatric patients with relapsed or progressive neuroblastomarelapsed or progressive neuroblastoma in pediatric patients of 1 to 18 yearsEUCTR2007-007974-45-DEAMC47
已完成
2 期
Phase II trial of the combination of gemcitabine and 131I-MIBG therapy in paediatric patients with relapsed or progressive neuroblastomaNL-OMON39557Academisch Medisch Centrum16
进行中（未招募）
不适用
A phase II study of the combination of gemcitabine with 131I-MIBG therapy for children with neuroblastoma without other treatment options.relapsed or progressive neuroblastoma in pediatric patients of 1 to 18 yearsEUCTR2007-007974-45-NLAMC47